Marker Therapeutics (MRKR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Marker Therapeutics is making strides in its clinical and financial fronts with significant progress in its Phase 1 APOLLO study for lymphoma and a financial boost from two NIH grants. As they gear up to release preliminary data, the company remains focused on advancing its T cell-based therapies for challenging cancers.
For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.
